×
About 5,675 results

ALLMedicine™ Calcitonin Gene-related Peptide Center

Research & Reviews  2,675 results

Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acu...
https://doi.org/10.1097/MD.0000000000024741
Medicine Zhang Z, Shu Y et. al.

Mar 5th, 2021 - The objective of this study is to systematically evaluate the efficacy and safety of the calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant for the treatment of acute migraine. Randomized controlled trials (RCTs) of ubrogepant f...

Evaluating rimegepant for the treatment of migraine.
https://doi.org/10.1080/14656566.2021.1895749
Expert Opinion on Pharmacotherapy; de Vries T, Al-Hassany L et. al.

Mar 2nd, 2021 - Calcitonin gene-related peptide (CGRP) is a vasodilatory neuropeptide that plays an essential role in the pathophysiology of migraine, a highly disabling neurovascular disorder characterized by severe headache attacks. Rimegepant is a small-molecu...

Calcitonin Gene-Related Peptide Protects Against Cardiovascular Dysfunction Independent...
https://doi.org/10.1161/HYPERTENSIONAHA.120.14851
Hypertension (Dallas, Tex. : 1979); Argunhan F, Thapa D et. al.

Mar 1st, 2021 - The neuropeptide CGRP (calcitonin gene-related peptide) is a potent vasodilator, with a cardioprotective role, although the precise mechanisms are unclear. Here we show the ability of endogenous and exogenous CGRP to restore blood pressure, when n...

The expression of substance P and calcitonin gene-related peptide is associated with th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898744
BMC Musculoskeletal Disorders; Han SH, Kim HK et. al.

Feb 22nd, 2021 - In this study, we investigated whether substance P (SP) or calcitonin gene-related peptide (CGRP) expression is associated with tendon degeneration in patients with lateral epicondylitis. Twenty-nine patients who underwent surgical treatment for l...

see more →

Guidelines  1 results

European headache federation guideline on the use of monoclonal antibodies acting on th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734227
The Journal of Headache and Pain; Sacco S, Bendtsen L et. al.

Jan 17th, 2019 - Monoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor (erenumab) and thr...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  2,813 results

Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acu...
https://doi.org/10.1097/MD.0000000000024741
Medicine Zhang Z, Shu Y et. al.

Mar 5th, 2021 - The objective of this study is to systematically evaluate the efficacy and safety of the calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant for the treatment of acute migraine. Randomized controlled trials (RCTs) of ubrogepant f...

Evaluating rimegepant for the treatment of migraine.
https://doi.org/10.1080/14656566.2021.1895749
Expert Opinion on Pharmacotherapy; de Vries T, Al-Hassany L et. al.

Mar 2nd, 2021 - Calcitonin gene-related peptide (CGRP) is a vasodilatory neuropeptide that plays an essential role in the pathophysiology of migraine, a highly disabling neurovascular disorder characterized by severe headache attacks. Rimegepant is a small-molecu...

Calcitonin Gene-Related Peptide Protects Against Cardiovascular Dysfunction Independent...
https://doi.org/10.1161/HYPERTENSIONAHA.120.14851
Hypertension (Dallas, Tex. : 1979); Argunhan F, Thapa D et. al.

Mar 1st, 2021 - The neuropeptide CGRP (calcitonin gene-related peptide) is a potent vasodilator, with a cardioprotective role, although the precise mechanisms are unclear. Here we show the ability of endogenous and exogenous CGRP to restore blood pressure, when n...

The expression of substance P and calcitonin gene-related peptide is associated with th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898744
BMC Musculoskeletal Disorders; Han SH, Kim HK et. al.

Feb 22nd, 2021 - In this study, we investigated whether substance P (SP) or calcitonin gene-related peptide (CGRP) expression is associated with tendon degeneration in patients with lateral epicondylitis. Twenty-nine patients who underwent surgical treatment for l...

see more →

News  181 results

CGRPs Promising for Prevention of Chronic Cluster Headache
https://www.staging.medscape.com/viewarticle/937760

Sep 20th, 2020 - Treatment with calcitonin gene-related peptide (CGRP) monoclonal antibodies may reduce the frequency of chronic cluster headache (CCH) attacks in patients with an inadequate response to other preventive medications, new research shows. In findings...

CGRPs Promising for Prevention of Chronic Cluster Headache
https://www.medscape.com/viewarticle/937760

Sep 20th, 2020 - Treatment with calcitonin gene-related peptide (CGRP) monoclonal antibodies may reduce the frequency of chronic cluster headache (CCH) attacks in patients with an inadequate response to other preventive medications, new research shows. In findings...

FDA Drug Approvals, Internal Medicine — 2020 Midyear Review
https://reference.staging.medscape.com/viewarticle/935373

Aug 13th, 2020 - Gastroenterology Pizensy (lactitol) Lactitol exerts an osmotic effect, causing an influx of water into the small intestine that results in a laxative effect in the colon. It is indicated for adults with chronic idiopathic constipation . Approval w...

Galcanezumab Looks Promising for Treatment-Resistant Migraine
https://www.medscape.com/viewarticle/931296

May 27th, 2020 - The calcitonin gene-related peptide monoclonal antibody galcanezumab (Emgality, Lilly) compared favorably to placebo for reducing the number of average monthly migraine days in a new study of people with treatment-resistant migraine headaches. "Th...

Galcanezumab Looks Promising for Treatment-Resistant Migraine
https://www.staging.medscape.com/viewarticle/931296

May 27th, 2020 - The calcitonin gene-related peptide monoclonal antibody galcanezumab (Emgality, Lilly) compared favorably to placebo for reducing the number of average monthly migraine days in a new study of people with treatment-resistant migraine headaches. "Th...

see more →